SHPGY » Topics » Registered in England 2883758 Registered Office as above

This excerpt taken from the SHPGY 8-K filed Mar 19, 2007.

Registered in England 2883758 Registered Office as above






Shire’s focused strategy is to develop and market products for specialty physicians. Shire’s in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe.

For further information on Shire, please visit the Company’s website: www.shire.com.

 

 

 

 

These excerpts taken from the SHPGY 8-K filed Mar 7, 2007.

Registered in England 2883758 Registered Office as above






Shire’s focused strategy is to develop and market products for specialty physicians. Shire’s in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe.

For further information on Shire, please visit the Company’s website: www.shire.com.

 

 

 

 

Registered in England 2883758 Registered Office as above






Shire’s focused strategy is to develop and market products for specialty physicians. Shire’s in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe.

For further information on Shire, please visit the Company’s website: www.shire.com.

 

 


These excerpts taken from the SHPGY 8-K filed Mar 5, 2007.

Registered in England 2883758 Registered Office as above






believes that a carefully selected portfolio of products with a strategically aligned and relatively small-scale sales force will deliver strong results.

Shire’s focused strategy is to develop and market products for specialty physicians. Shire’s in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe.

For further information on Shire, please visit the Company’s website: www.shire.com.

 

 

 

 

Registered in England 2883758 Registered Office as above






Shire’s focused strategy is to develop and market products for specialty physicians. Shire’s in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe.

For further information on Shire, please visit the Company’s website: www.shire.com.

 

 

 

 

Registered in England 2883758 Registered Office as above






attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions. Shire believes that a carefully selected portfolio of products with a strategically aligned and relatively small-scale sales force will deliver strong results.

Shire’s focused strategy is to develop and market products for specialty physicians. Shire’s in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe.

For further information on Shire, please visit the Company’s website: www.shire.com.

 

 

 

 

 

These excerpts taken from the SHPGY 8-K filed Mar 1, 2007.

Registered in England 2883758 Registered Office as above






Shire’s strategic goal is to become the leading specialty pharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions. Shire believes that a carefully selected portfolio of products with a strategically aligned and relatively small-scale sales force will deliver strong results.

Shire’s focused strategy is to develop and market products for specialty physicians. Shire’s in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe.

For further information on Shire, please visit the Company’s website: www.shire.com.

Registered in England 2883758 Registered Office as above






 

Anita Graham ADR 8,334 $64.10
          *Awards to Executive Directors are subject to performance targets

The PSP awards will normally vest after three years, subject to any performance targets. Once vested, sufficient ordinary shares or ADRs will be transferred or allotted to the participant within 30 days. No consideration was paid for the grant of PSP awards.

T May
Company Secretary

Registered in England 2883758 Registered Office as above






attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions. Shire believes that a carefully selected portfolio of products with a strategically aligned and relatively small-scale sales force will deliver strong results.

Shire’s focused strategy is to develop and market products for specialty physicians. Shire’s in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe.

For further information on Shire, please visit the Company’s website: www.shire.com.

Registered in England 2883758 Registered Office as above






128,400 STATE STREET BANK AND TR CO FMRCO
22,980 STATE STREET BANK AND TR CO FMR
82,254 STATE STREET BANK AND TR CO FICL
14,400 NORTHERN TRUST LONDON FMRCO
89,400 NORTHERN TRUST CO FMTC
37,700 MELLON BANK N.A. FMTC
53,400 MELLON BANK N.A. FMRCO
65,800 JPMORGAN CHASE BANK FPM
81,600 JPMORGAN CHASE BANK FMTC
2,309,600 JPMORGAN CHASE BANK FMRCO
3,474,800 BROWN BROTHERS HARRIMAN AND CO FMRCO
29,600 BANK OF NEW YORK FMRCO
108,000 BANK OF NEW YORK FMTC

FMR Corp is the parent holding company of Fidelity Management and Research Company (FMRCO), investment manager for US mutual funds and Fidelity Management Trust Company (FMTC), a US state chartered bank which acts as trustee or investment manager of various pension and trust accounts.

Registered in England 2883758 Registered Office as above






Proxy Voting:

10. Name of the proxy holder: N/A
11. Number of voting rights proxy holder will cease to hold: N/A
12. Date on which proxy holder will cease to hold voting rights: N/A

13. Additional information: Notification using the total voting rights figures of 511,667,558
First notification under the DTR Sourcebook
14. Contact name: Helen Lewis
15. Contact telephone number: 020 7528 6742

Contact at Shire plc: Vivienne Hemming, Deputy Company Secretary, 01256 894276

Registered in England 2883758 Registered Office as above






13. Additional information:  
14. Contact name: Joanne Wall
15. Contact telephone number: 020 7051 1704

Contact at Shire plc: Vivienne Hemming, Deputy Company Secretary, 01256 894276

Registered in England 2883758 Registered Office as above






Shire’s focused strategy is to develop and market products for specialty physicians. Shire’s in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe.

For further information on Shire, please visit the Company’s website: www.shire.com.

These excerpts taken from the SHPGY 8-K filed Feb 23, 2007.

Registered in England 2883758 Registered Office as above






believes that a carefully selected portfolio of products with a strategically aligned and relatively small-scale sales force will deliver strong results.

Shire’s focused strategy is to develop and market products for specialty physicians. Shire’s in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe.

For further information on Shire, please visit the Company’s website:  www.shire.com.

 

Registered in England 2883758 Registered Office as above






believes that a carefully selected portfolio of products with a strategically aligned and relatively small-scale sales force will deliver strong results.

Shire’s focused strategy is to develop and market products for specialty physicians. Shire’s in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe.

For further information on Shire, please visit the Company’s website:
www.shire.com.

Registered in England 2883758 Registered Office as above






Shire’s focused strategy is to develop and market products for specialty physicians. Shire’s in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe.

For further information on Shire, please visit the Company’s website: www.shire.com.

These excerpts taken from the SHPGY 8-K filed Feb 15, 2007.

Registered in England 2883758 Registered Office as above






target new therapeutic areas to the extent opportunities arise through acquisitions. Shire believes that a carefully selected portfolio of products with a strategically aligned and relatively small-scale sales force will deliver strong results.

Shire’s focused strategy is to develop and market products for specialty physicians. Shire’s in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe.

For further information on Shire, please visit the Company’s website: www.shire.com.

 

Registered in England 2883758 Registered Office as above






A replay of the presentation will be available for two weeks. Details are as follows:

UK Dial In Number 0800 358 2189
USA Toll Free Number 1 866 676 5865
Std International Number +44 (0) 20 8609 0289
Replay Access Number 163318#
Webcast Replay www.shire.com, in the Investor Relations/Events
  section

For further information please contact:  
     
Investor Relations Souheil Salah (Rest of the World)  +44 1256 894 160
  Heidi Wunder (North America)  +1 484 595 8970

This excerpt taken from the SHPGY 8-K filed Jan 24, 2007.

Registered in England 2883758 Registered Office as above






with the Securities and Exchange Commission, particularly Shire plc’s Annual Report on Form 10-K for the year ended December 31, 2005.

 

 

This excerpt taken from the SHPGY 8-K filed Jan 19, 2007.


Registered in England 2883758 Registered Office as above






believes that a carefully selected portfolio of products with a strategically aligned and relatively small-scale sales force will deliver strong results.

Shire’s focused strategy is to develop and market products for specialty physicians. Shire’s in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe.

For further information on Shire, please visit the Company’s website: www.shire.com.

 

This excerpt taken from the SHPGY 8-K filed Jan 17, 2007.


Registered in England 2883758 Registered Office as above






Giuliani S.p.A., founded in 1889, is a privately owned specialty pharmaceutical company with Headquarters in Milan, Italy. It develops new products with high unmet medical need and substantial market opportunity. It is focused on developing and marketing products for the treatment and management of gastrointestinal (ulcerative colitis and Crohn's disease), metabolic (food intolerance) and dermatological (hair loss) disorders.

This excerpt taken from the SHPGY 8-K filed Jan 11, 2007.

Registered in England 2883758 Registered Office as above






For further information please contact:  
Investor Relations Cléa Rosenfeld (Rest of the World) +44 1256 894 160
  Brian Piper (North America) +1 484 595
Media Jessica Mann (Rest of the World) +44 1256 894 280 8252
  Matthew Cabrey (North America) +1 484 595 8248

References
1. European Public Assessment Report for Elaprase (idursulfase) http://www.emea.europa.eu
2. Froissart R et al. Mucopolysaccharidosis type II – genotype/phenotype aspects. Acta Paediatr suppl. 2002;439 :82-87
3. Kolodny EH et al. Storage diseases of the reticuloendothelial system. In: Nathan DG et al. Nathan and Oski’s Hematology of Infancy and Childhood. 5th ed. Philadelphia, Pa: WB Saunders Co;1998:1461-1507
4. Vellodi A et al. Long-term follow-up following bone marrow transplantation for Hunter Disease. J Inher Metab Dis, 1999:22:638-648
5. Hunter Syndrome. National Organization for Rare Disorders. www.rarediseases.org. January 2006
6. Medline Plus. Hunter syndrome. http://www.nlm.nih.gov/medlineplus/ency/article/001203.htm.Accessed Nov 2006
This excerpt taken from the SHPGY 8-K filed Dec 27, 2006.

Registered in England 2883758 Registered Office as above






ability to achieve certain threshold sales targets; our estimates regarding our capital requirements and our needs for additional financing; the likelihood of obtaining favorable scheduling and labeling of our drug products; the likelihood of regulatory approval under the Federal Food, Drug, and Cosmetic Act without having to conduct long and costly trials to generate all of the data which are often required in connection with a traditional new chemical entity; our ability to develop safer and improved versions of widely prescribed drugs using our Carrierwave (TM) technology; our success in developing our own sales and marketing capabilities for our lead product candidate, NRP104; and our ability to obtain favorable patent claims. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof. New River Pharmaceuticals does not undertake any obligation to republish revised forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. Readers are also urged to carefully review and consider the various disclosures in New River Pharmaceuticals’ annual report on Form 10-K, filed with the SEC on March 15, 2006, as well as other public filings with the SEC.

This excerpt taken from the SHPGY 8-K filed Dec 21, 2006.

Registered in England 2883758 Registered Office as above






target new therapeutic areas to the extent opportunities arise through acquisitions. Shire believes that a carefully selected portfolio of products with a strategically aligned and relatively small-scale sales force will deliver strong results.

Shire’s focused strategy is to develop and market products for specialty physicians. Shire’s in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe.

For further information on Shire, please visit the Company’s website: www.shire.com.

 

 

 

 

 

This excerpt taken from the SHPGY 8-K filed Dec 15, 2006.

Registered in England 2883758 Registered Office as above






Shire’s focused strategy is to develop and market products for specialty physicians. Shire’s in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe.

For further information on Shire, please visit the Company’s website: www.shire.com.

 

 

 

This excerpt taken from the SHPGY 8-K filed Dec 14, 2006.

Registered in England 2883758 Registered Office as above






SPD465 (extended release triple-bead mixed amphetamine salts) (ADHD), MESAVANCE (mesalamine) with MMX technology (SPD476) (ulcerative colitis), ELAPRASE (idursulfase) (Hunter Syndrome) and NRP104 (lisdexamfetamine dimesylate) (ADHD), including its scheduling classification by the Drug Enforcement Administration in the United States; Shire's ability to secure new products for commercialization and/or development; and other risks and uncertainties detailed from time to time in Shire's and its predecessor registrant Shire Pharmaceuticals Group plc's filings with the Securities and Exchange Commission, particularly Shire plc’s Annual Report on Form 10-K for the year ended December 31, 2005.

 

 

 

This excerpt taken from the SHPGY 8-K filed Dec 14, 2006.

Registered in England 2883758 Registered Office as above






dimesylate) (ADHD), including its scheduling classification by the Drug Enforcement Administration in the United States; Shire's ability to secure new products for commercialization and/or development; and other risks and uncertainties detailed from time to time in Shire's and its predecessor registrant Shire Pharmaceuticals Group plc's filings with the Securities and Exchange Commission, particularly Shire plc’s Annual Report on Form 10-K for the year ended December 31, 2005.






This excerpt taken from the SHPGY 8-K filed Dec 6, 2006.

Registered in England 2883758 Registered Office as above






Number and class of securities originally listed and the date of admission 3,000,000 on 2 February 2006

Total number of securities in issue at the end of the period

503,484,082


Name of contact: Vivienne Hemming – Deputy Company Secretary

Address of contact:

Shire plc, Lime Tree Way, Hampshire International Business Park, Chinham, Basingstoke, RG24 8EP

Telephone number of contact:

+44 1256 894 276


These excerpts taken from the SHPGY 8-K filed Nov 22, 2006.

Registered in England 2883758 Registered Office as above






believes that a carefully selected portfolio of products with a strategically aligned and relatively small-scale sales force will deliver strong results.

Shire’s focused strategy is to develop and market products for specialty physicians. Shire’s in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe.

For further information on Shire, please visit the Company’s website: www.shire.com.

 

 

Registered in England 2883758 Registered Office as above






believes that a carefully selected portfolio of products with a strategically aligned and relatively small-scale sales force will deliver strong results.

Shire’s focused strategy is to develop and market products for specialty physicians. Shire’s in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe.

For further information on Shire, please visit the Company’s website: www.shire.com.

 

This excerpt taken from the SHPGY 8-K filed Nov 17, 2006.

Registered in England 2883758 Registered Office as above






Shire’s focused strategy is to develop and market products for specialty physicians. Shire’s in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe.

For further information on Shire, please visit the Company’s website: www.shire.com.

This excerpt taken from the SHPGY 8-K filed Nov 9, 2006.

Registered in England 2883758 Registered Office as above






Shire’s focused strategy is to develop and market products for specialty physicians. Shire’s in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe.

For further information on Shire, please visit the Company’s website: www.shire.com.

This excerpt taken from the SHPGY 8-K filed Oct 31, 2006.

Registered in England 2883758 Registered Office as above






believes that a carefully selected portfolio of products with a strategically aligned and relatively small-scale sales force will deliver strong results.

Shire’s focused strategy is to develop and market products for specialty physicians. Shire’s in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe.

For further information on Shire, please visit the Company’s website: www.shire.com.

This excerpt taken from the SHPGY 8-K filed Oct 20, 2006.

Registered in England 2883758 Registered Office as above






licensed, this therapy will provide physicians with the first and only treatment for Hunter syndrome since it was first recognised over 100 years ago.”

- ends -

About ELAPRASE
ELAPRASE is a purified form of the lysosomal enzyme iduronate-2-sulfatase and is produced by recombinant DNA technology in a human cell line.

About Hunter Outcome Survey
Shire is actively tracking health data among individuals affected by Hunter syndrome as part of the company’s long-term outcome survey, called the Hunter Outcome Survey (HOS). HOS is designed to support the gathering, analysis, reporting and sharing of data from around the world about Hunter syndrome. Shire believes that the inclusion of all people affected by Hunter syndrome and the analysis and dissemination of this information will allow for further understanding of Hunter syndrome and disease education on a global scale.

About Hunter Syndrome
Hunter syndrome (MPS II) is a serious genetic disorder mainly affecting males. People with this condition are lacking an enzyme (iduronate sulfatase), which breaks down mucopolysaccharides (long chains of sugar molecule used in the building of connective tissues in the body), also known as glycosaminoglycans or GAG. The incompletely broken down GAG remains in cells throughout the body causing progressive damage.

Babies may show little sign of the disease but, as more and more cells become damaged, symptoms start to appear. Physical manifestations for some people with Hunter syndrome may include distinct facial features, a large head and an enlarged abdomen. People with Hunter syndrome may also experience hearing loss, thickening of the heart valves leading to a decline in cardiac function, obstructive airway disease, sleep apnoea, and enlargement of the liver and spleen. In some cases, central nervous system involvement leads to progressive neurological decline. Life expectancy for people with the severe form of this syndrome is commonly 10 to 20 years.

Shire estimates that there are approximately 2,000 patients worldwide afflicted with Hunter Syndrome in countries where reimbursement may be possible.

These excerpts taken from the SHPGY 8-K filed Oct 12, 2006.

Registered in England 2883758 Registered Office as above






Shire’s focused strategy is to develop and market products for specialty physicians. Shire’s in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe.

For further information on Shire, please visit the Company’s website: www.shire.com.

Registered in England 2883758 Registered Office as above






Shire’s focused strategy is to develop and market products for specialty physicians. Shire’s in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe.

For further information on Shire, please visit the Company’s website: www.shire.com.

This excerpt taken from the SHPGY 8-K filed Oct 10, 2006.

Registered in England 2883758 Registered Office as above






Under the terms of the agreement with New River, the parties will collaborate on NRP104 development, manufacturing, marketing and sale in the US. New River Pharmaceuticals will be financially and operationally responsible for clinical and manufacturing development. Shire will book the product sales and New River Pharmaceuticals will supply up to 25% of the sales effort under a co promotion right. Shire is obligated to give NRP104 marketing and promotional priority over its other oral ADHD stimulants should NRP104’s label contain a claim that it has decreased potential for abuse or overdose protection.

If NRP104 is approved with a Schedule III, IV or V classification or is unscheduled (“favorable scheduling”), Shire will pay New River a $300 million milestone payment. US operating profit will be divided as follows: Shire will retain 75 percent of profits for the first two years following launch, and the parties will share the profits equally thereafter.

In the event that NRP104 receives a final Schedule II classification, no milestone payment will be payable by Shire to New River upon approval. Division of profits will be calculated under an alternative profit sharing scheme. New River’s share of U.S. product profits for the first two years will be at least 25%, though it may increase to a value determined by a preset formula; for following years, it will be at least 50%, though it may increase to a value determined by a preset formula thereafter. These formulas, which include yearly threshold sales, will be included in the 8-K to be filed.

If NRP104 is approved with a Schedule II classification on approval and it gets favorable scheduling within one year of the first commercial sale, Shire will pay New River a $200 million milestone payment; if favorable scheduling occurs by the third anniversary, the milestone payment will be $100 million. Upon favorable scheduling being achieved under each of these scenarios, the profit sharing formula reverts to that applicable to favorable scheduling from product approval.

In addition, New River will be entitled to a $100 million milestone payment at the end of the first calendar year in which cumulative worldwide net sales of all collaboration products during that calendar year exceed $1 billion. Shire intends to capitalize and amortize any milestone payment and sales bonus over the life of the product.

Shire is entitled to terminate the agreement until 30 days following approval of NRP104. If Shire terminates before regulatory approval, no payment would be due Shire. If Shire terminates after approval and NRP104 has received a favorable scheduling assignment, no payment would be due Shire. If the approved NRP104 has received a Schedule II classification, Shire would be entitled to a $50 million termination payment, payable in cash, New River common stock, or an unsecured, 5-year promissory note, as will be agreed upon by Shire and New River.

On August 14, 2006 Shire announced that it had settled all pending litigation with Barr Laboratories, Inc. in connection with Barr’s Abbreviated New Drug Application and its attempt to market generic versions of Shire’s ADDERALL XR (extended-release mixed amphetamine salts) for the treatment of ADHD. Barr will not be permitted to market a generic version of ADDERALL XR in the United States until April 1, 2009, except under certain limited circumstances, such as the launch of another party’s generic version of ADDERALL XR.

-ends-

This excerpt taken from the SHPGY 8-K filed Oct 5, 2006.

Registered in England 2883758 Registered Office as above






For further information on Shire, please visit the Company’s website: www.shire.com.


These excerpts taken from the SHPGY 8-K filed Oct 4, 2006.

Registered in England 2883758 Registered Office as above






For further information please contact:  
       
Investor Relations   Cléa Rosenfeld (Rest of the World) +44 1256 894 160
    Brian Piper (North America)   +1 484 595 8252 
       
Media    Jessica Mann (Rest of the World)   +44 1256 894 280 
    Matthew Cabrey (North America)   +1 484 595 8248 

Registered in England 2883758 Registered Office as above






believes that a carefully selected portfolio of products with a strategically aligned and relatively small-scale sales force will deliver strong results.

Shire’s focused strategy is to develop and market products for specialty physicians. Shire’s in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe.

For further information on Shire, please visit the Company’s website: www.shire.com.

Registered in England 2883758 Registered Office as above






gastrointestinal (GI) and renal diseases. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions. Shire believes that a carefully selected portfolio of products with a strategically aligned and relatively small-scale sales force will deliver strong results.

Shire’s focused strategy is to develop and market products for specialty physicians. Shire’s in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe.

For further information on Shire, please visit the Company’s website: www.shire.com.

 

Registered in England 2883758 Registered Office as above





Shire’s focused strategy is to develop and market products for specialty physicians. Shire’s in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe.

For further information on Shire, please visit the Company’s website: www.shire.com.

 

Registered in England 2883758 Registered Office as above






Shire’s focused strategy is to develop and market products for specialty physicians. Shire’s in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe.

For further information on Shire, please visit the Company’s website: www.shire.com

 

Registered in England 2883758 Registered Office as above






believes that a carefully selected portfolio of products with a strategically aligned and relatively small-scale sales force will deliver strong results.

Shire’s focused strategy is to develop and market products for specialty physicians. Shire’s in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe.

For further information on Shire, please visit the Company’s website: www.shire.com.

 

 

Registered in England 2883758 Registered Office as above






Shire’s focused strategy is to develop and market products for specialty physicians. Shire’s in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe.

For further information on Shire, please visit the Company’s website: www.shire.com.

These excerpts taken from the SHPGY 8-K filed Oct 2, 2006.


Registered in England 2883758 Registered Office as above






Shire’s focused strategy is to develop and market products for specialty physicians. Shire’s in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe.

For further information on Shire, please visit the Company’s website: www.shire.com.


Registered in England 2883758 Registered Office as above






Shire’s focused strategy is to develop and market products for specialty physicians. Shire’s in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe.

For further information on Shire, please visit the Company’s website: www.shire.com.


Registered in England 2883758 Registered Office as above






believes that a carefully selected portfolio of products with a strategically aligned and relatively small-scale sales force will deliver strong results.

Shire’s focused strategy is to develop and market products for specialty physicians. Shire’s in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe.

For further information on Shire, please visit the Company’s website: www.shire.com.

Registered in England 2883758 Registered Office as above






believes that a carefully selected portfolio of products with a strategically aligned and relatively small-scale sales force will deliver strong results.

Shire’s focused strategy is to develop and market products for specialty physicians. Shire’s in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe.

For further information on Shire, please visit the Company’s website: www.shire.com.

This excerpt taken from the SHPGY 8-K filed Sep 26, 2006.


Registered in England 2883758 Registered Office as above






believes that a carefully selected portfolio of products with a strategically aligned and relatively small-scale sales force will deliver strong results.

Shire’s focused strategy is to develop and market products for specialty physicians. Shire’s in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe.

For further information on Shire, please visit the Company’s website: www.shire.com.


These excerpts taken from the SHPGY 8-K filed Sep 22, 2006.

Registered in England 2883758 Registered Office as above





believes that a carefully selected portfolio of products with a strategically aligned and relatively small-scale sales force will deliver strong results.

Shire’s focused strategy is to develop and market products for specialty physicians. Shire’s in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe.

For further information on Shire, please visit the Company’s website: www.shire.com.

Registered in England 2883758 Registered Office as above






believes that a carefully selected portfolio of products with a strategically aligned and relatively small-scale sales force will deliver strong results.

Shire’s focused strategy is to develop and market products for specialty physicians. Shire’s in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe.

For further information on Shire, please visit the Company’s website: www.shire.com.

Registered in England 2883758 Registered Office as above






believes that a carefully selected portfolio of products with a strategically aligned and relatively small-scale sales force will deliver strong results.

Shire’s focused strategy is to develop and market products for specialty physicians. Shire’s in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe.

For further information on Shire, please visit the Company’s website: www.shire.com.

These excerpts taken from the SHPGY 8-K filed Sep 19, 2006.


Registered in England 2883758 Registered Office as above






believes that a carefully selected portfolio of products with a strategically aligned and relatively small-scale sales force will deliver strong results.

Shire’s focused strategy is to develop and market products for specialty physicians. Shire’s in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe.

For further information on Shire, please visit the Company’s website: www.shire.com.


Registered in England 2883758 Registered Office as above






believes that a carefully selected portfolio of products with a strategically aligned and relatively small-scale sales force will deliver strong results.

Shire’s focused strategy is to develop and market products for specialty physicians. Shire’s in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe.

For further information on Shire, please visit the Company’s website: www.shire.com.


Registered in England 2883758 Registered Office as above




These excerpts taken from the SHPGY 8-K filed Sep 15, 2006.

Registered in England 2883758 Registered Office as above






believes that a carefully selected portfolio of products with a strategically aligned and relatively small-scale sales force will deliver strong results.

Shire’s focused strategy is to develop and market products for specialty physicians. Shire’s in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe.

For further information on Shire, please visit the Company’s website: www.shire.com.

 

Registered in England 2883758 Registered Office as above






believes that a carefully selected portfolio of products with a strategically aligned and relatively small-scale sales force will deliver strong results.

Shire’s focused strategy is to develop and market products for specialty physicians. Shire’s in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe.

For further information on Shire, please visit the Company’s website: www.shire.com.

 

This excerpt taken from the SHPGY 8-K filed Sep 12, 2006.

Registered in England 2883758 Registered Office as above






target new therapeutic areas to the extent opportunities arise through acquisitions. Shire believes that a carefully selected portfolio of products with a strategically aligned and relatively small-scale sales force will deliver strong results.

Shire’s focused strategy is to develop and market products for specialty physicians. Shire’s in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe.

For further information on Shire, please visit the Company’s website: www.shire.com.

 

This excerpt taken from the SHPGY 8-K filed Sep 7, 2006.

Registered in England 2883758 Registered Office as above






believes that a carefully selected portfolio of products with a strategically aligned and relatively small-scale sales force will deliver strong results.

Shire’s focused strategy is to develop and market products for specialty physicians. Shire’s in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe.

For further information on Shire, please visit the Company’s website: www.shire.com.

 

This excerpt taken from the SHPGY 8-K filed Sep 6, 2006.

Registered in England 2883758 Registered Office as above






believes that a carefully selected portfolio of products with a strategically aligned and relatively small-scale sales force will deliver strong results.

Shire’s focused strategy is to develop and market products for specialty physicians. Shire’s in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe.

For further information on Shire, please visit the Company’s website: www.shire.com.

 

 

 

These excerpts taken from the SHPGY 8-K filed Sep 5, 2006.

Registered in England 2883758 Registered Office as above




believes that a carefully selected portfolio of products with a strategically aligned and relatively small-scale sales force will deliver strong results.

Shire’s focused strategy is to develop and market products for specialty physicians. Shire’s in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe.

For further information on Shire, please visit the Company’s website: www.shire.com.


Registered in England 2883758 Registered Office as above






believes that a carefully selected portfolio of products with a strategically aligned and relatively small-scale sales force will deliver strong results.

Shire’s focused strategy is to develop and market products for specialty physicians. Shire’s in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe.

For further information on Shire, please visit the Company’s website: www.shire.com.

 

This excerpt taken from the SHPGY 8-K filed Aug 31, 2006.

Registered in England 2883758 Registered Office as above






target new therapeutic areas to the extent opportunities arise through acquisitions. Shire believes that a carefully selected portfolio of products with a strategically aligned and relatively small-scale sales force will deliver strong results.

Shire’s focused strategy is to develop and market products for specialty physicians. Shire’s in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe.

For further information on Shire, please visit the Company’s website: www.shire.com.

 

These excerpts taken from the SHPGY 8-K filed Aug 25, 2006.

Registered in England 2883758 Registered Office as above






Shire’s focused strategy is to develop and market products for specialty physicians. Shire’s in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe.

For further information on Shire, please visit the Company’s website: www.shire.com.


Registered in England 2883758 Registered Office as above






believes that a carefully selected portfolio of products with a strategically aligned and relatively small-scale sales force will deliver strong results.

Shire’s focused strategy is to develop and market products for specialty physicians. Shire’s in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe.

For further information on Shire, please visit the Company’s website: www.shire.com.

Registered in England 2883758 Registered Office as above






plc's results could be materially affected. The risks and uncertainties include, but are not limited to: risks associated with the inherent uncertainty of pharmaceutical research, product development, manufacturing and commercialization; the impact of competitive products, including, but not limited to, the impact of those on Shire plc's Attention Deficit and Hyperactivity Disorder ("ADHD") franchise; patents, including but not limited to, legal challenges relating to Shire plc's ADHD franchise; government regulation and approval, including but not limited to the expected product approval dates of CONNEXYN™ (SPD503) (ADHD), SPD465 (ADHD), MESAVANCE TM (SPD476) (ulcerative colitis), and NRP104 (ADHD), including its scheduling classification by the Drug Enforcement Administration in the United States; Shire plc's ability to secure new products for commercialization and/or development; and other risks and uncertainties detailed from time to time in Shire plc's and its predecessor registrant Shire Pharmaceuticals Group plc's filings with the US Securities and Exchange Commission, particularly Shire plc's Annual Report on Form 10-K for the year ended December 31, 2005.

# # #

Diagnostic and Statistical Manual of Mental Disorders is a registered trademark of the American Psychiatric Association.

 

These excerpts taken from the SHPGY 8-K filed Aug 24, 2006.

Registered in England 2883758 Registered Office as above






Shire’s focused strategy is to develop and market products for specialty physicians. Shire’s in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe.

For further information on Shire, please visit the Company’s website: www.shire.com.

Registered in England 2883758 Registered Office as above






Shire’s focused strategy is to develop and market products for specialty physicians. Shire’s in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe.

For further information on Shire, please visit the Company’s website: www.shire.com.

These excerpts taken from the SHPGY 8-K filed Aug 22, 2006.

Registered in England 2883758 Registered Office as above






believes that a carefully selected portfolio of products with a strategically aligned and relatively small-scale sales force will deliver strong results.

Shire’s focused strategy is to develop and market products for specialty physicians. Shire’s in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe.

For further information on Shire, please visit the Company’s website: www.shire.com.




Registered in England 2883758 Registered Office as above






believes that a carefully selected portfolio of products with a strategically aligned and relatively small-scale sales force will deliver strong results.

Shire’s focused strategy is to develop and market products for specialty physicians. Shire’s in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe.

For further information on Shire, please visit the Company’s website: www.shire.com.



Registered in England 2883758 Registered Office as above






believes that a carefully selected portfolio of products with a strategically aligned and relatively small-scale sales force will deliver strong results.

Shire’s focused strategy is to develop and market products for specialty physicians. Shire’s in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe.

For further information on Shire, please visit the Company’s website: www.shire.com.

 

This excerpt taken from the SHPGY 8-K filed Aug 21, 2006.

Registered in England 2883758 Registered Office as above






believes that a carefully selected portfolio of products with a strategically aligned and relatively small-scale sales force will deliver strong results.

Shire’s focused strategy is to develop and market products for specialty physicians. Shire’s in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe.

For further information on Shire, please visit the Company’s website: www.shire.com.


This excerpt taken from the SHPGY 8-K filed Aug 16, 2006.

Registered in England 2883758 Registered Office as above






European markets of the UK, Germany, France, Italy and Spain and other areas, excluding North America and to the subsequent sales they will generate on a royalty-free basis.

Duramed has also agreed to purchase Shire’s ADDERALL® (immediate-release mixed amphetamine sales) product for $63 million. This transaction is subject to reporting under the United States Hart-Scott-Rodino Act.

Matthew Emmens, Shire Chief Executive Officer stated: “We are very pleased to have reached this settlement on terms that are consistent with our beliefs that Shire’s patents are valid and enforceable and infringed by would-be generic competitors. We are also excited about the opportunity of a new development and licensing agreement in the specialty area of women’s health, particularly in Europe.”

The agreements will be submitted to the United States Federal Trade Commission as required by law and become effective upon the Courts’ signing of consent judgments for all of the litigations.

This excerpt taken from the SHPGY 8-K filed Jul 25, 2006.

Registered in England 2883758 Registered Office as above






Shire submitted a Marketing Authorization Application (MAA) for ELAPRASE to the European Medicines Agency (EMEA) on December 1, 2005. Based on average evaluation times, Shire anticipates completion of the EMEA review by year end. In European countries that have mechanisms for pre-approval access, Shire has also submitted applications.

This excerpt taken from the SHPGY 8-K filed Jul 24, 2006.

Registered in England 2883758 Registered Office as above






For further information on ADHD please visit www.adderallxr.com, www.adhdsupport.com, www.CHADD.org or www.NMHA.org.

This excerpt taken from the SHPGY 8-K filed Jun 22, 2006.
Registered in England 2883758 Registered Office as above




9. To re-elect Dr Barry John
Price as a director
354,069,599
(99.37%)
2,231,923
(0.63%)
5,019,857
10. To re-elect Mr Angus Charles Russell
as a director
358,109,095
(99.74%)
916,203
(0.26%)
2,296,081
11. To re-appoint Deloitte & Touch LLP as Auditors 350,604,574
(98.17%)
6,521,791
(1.83%)
4,195,014
12. To authorise the Audit Committee to
determine the remuneration of the Auditors
359,770,712
(99.67%)
1,187,866
(0.33%)
362,801
13. To approve the Directors’ Remuneration Report 339,634,086
(96.79%)
11,273,314
(3.21%)
10,413,979
14 To authorise the allotment of
shares
355,037,733
(98.29%)
6,159,314
(1.71%)
124,332
15. To authorise the
disapplication of pre-emption rights
358,499,820
(99.26%)
2,669,655
(0.74%)
152,904
16. To authorise market purchases 361,026,133 238,054 57,192
17. To authorise donations to EU
political organisations and EU
political expenditure
354,116,165
(98.53%)
5,286,233
(1.47%)
1,918,981

* These figures include discretionary votes
** Abstentions are not counted in the proportion of votes “for” or “against”
   
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki